FIRST IN CLASS1 Co-FORMULATION INSULIN

Key Challenges
& the need for
Innovation

1. Heise T et al. Diabetes Ther (2014) 5:255-265.

For Healthcare Professional and Educational Purpose Only

2020 @ Novo Nordisk A/S

Key Challenges with current insulin therapy in
people with T2DM

Inadequate Glycemic Control1,2 Treatment complexity3,4

Many patients have suboptimal glycemic Complex treatment regimens are associated
control, increasing the risk of complication with reduced adherence to treatment

References
1. Guigliano et al. Diabetes care. 2011;34(2):510-7
2. Stratton et al. BMJ. 2000;321(7258):405-12.
3. Peyrot et al. Diabet Med. 2012;29: 682-9
4. Jarab et al. Int J Clin Pharm. 2014; 36(4):725-33.
Key Challenges with current insulin therapy in
people with T2DM

>70% of patients with T2DM
using basal insulin are not at
HbA1c GOAL*1
Targeting BOTH FPG and Intensification from basal
PPG to basal – bolus is
is important for achieving COMPLEX4
optimal glycaemic control2,3 Multiple daily injection can be a
barrier for patients with diabetes

References
1. Mauricio D, et al. Diabetes Obes Metab. 2017 Aug;19(8):1155-1164
2. IDF 2011. Available at: http://www.idf.org/guideline-type-2-diabetes. Accessed: 12 March 2018.
3. American Diabetes Association. Glycemic Targets. Diabetes Care. 2017;(40);S48–S56. Available at:
http://care.diabetesjournals.org/content/40/Supplement_1/S48-56. Accessed: 12 March 2018.
4. Peyrot et al. Diabet Med. 2012;29: 682-9
 PowerPoint Presentation Date 4

There is a need for a EFFECTIVE and SIMPLE

solution

There is a need for a Co-Formulation insulin therapy that offers:

CONTROL SAFETY SIMPLICITY

Effective Reductions Low risk of Hypoglycemia A simpler, one-pen

in HbA1c to target, regimen with fewer
with both FPG and injections than basal
PPG control and bolus therapy
GENERIC NAME
INTRODUCING: The First Co-formulation
of a basal insulin with an ultra-long duration of action and a mealtime
insulin in one pen1,2

References
1. Ryzodeg®. Indonesia Prescribing Information 2018.
2. De Rycke A et al. European Endocrinology 2011;7(2):84-87
3. Heller et al. Diabetes Metab Res Rev. 2012;28:50-61

Atkin Ther Adv Chronic Dis 2015;6:375–88; Kruszynska et al. Diabetologia 1987;30:16–21
 PowerPoint Presentation Date 6

ETD, estimated treatment difference; FPG,

Onishi et al. Diabetes Obes Metab 2013;15:826–32
PowerPoint Presentation Date 7